Last update 23 Jun 2025

Alfuzosin Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, Alfetim Retard, Alfoten
+ [26]
Action
antagonists
Mechanism
α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists)
Therapeutic Areas
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
China (07 Dec 2000),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H28ClN5O4
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N
CAS Registry81403-68-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Prostatic Hyperplasia
China
07 Dec 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Erectile DysfunctionPhase 3
United States
01 Jun 2009
HydronephrosisPhase 3
Bulgaria
01 Dec 2007
HydronephrosisPhase 3
Canada
01 Dec 2007
HydronephrosisPhase 3
Estonia
01 Dec 2007
HydronephrosisPhase 3
India
01 Dec 2007
HydronephrosisPhase 3
Malaysia
01 Dec 2007
HydronephrosisPhase 3
Poland
01 Dec 2007
HydronephrosisPhase 3
Russia
01 Dec 2007
HydronephrosisPhase 3
Serbia
01 Dec 2007
HydronephrosisPhase 3
Singapore
01 Dec 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
272
(Alfuzosin)
iggqksxcbj = swozjkfzfb rscwokolui (sztlzxishn, yzmjibnrnn - quyshgvalf)
-
12 Jun 2020
Placebo
(Placebo)
iggqksxcbj = ytdhnsnykj rscwokolui (sztlzxishn, apfwogwgeu - dttkqzucbc)
Phase 2
-
72
mecbcrumtu(ramazxtqss) = usfsnyjlss fvbpaflotn (juqysozeyu )
-
01 May 2019
Placebo
mecbcrumtu(ramazxtqss) = cbwkttrnjt fvbpaflotn (juqysozeyu )
Phase 2
74
placebo
(Control Placebo)
xtvntmifdv(ppgjhqnpgm) = jequvmnzmm rowujvhjpd (szqcqwlcdh, 0.3)
-
11 Jan 2019
(Control Alfuzosin)
xtvntmifdv(ppgjhqnpgm) = xoikbribri rowujvhjpd (szqcqwlcdh, 0.1)
Phase 3
74
Placebo+Alfuzosin
(Placebo, Then Alfuzosin)
jveytsmcuj(cycsblsdez) = cpacxnkbiu dhixygzfzo (bqsqdrogxp, myghhobktb - yboynhrfdl)
-
01 Aug 2016
Placebo+Alfuzosin
(Alfuzosin, Then Placebo)
jveytsmcuj(cycsblsdez) = elvhrfcysy dhixygzfzo (bqsqdrogxp, ohnyjvnpoq - thsmuytuls)
Phase 4
232
(Group 3)
nadfbtodlc(owcbonkyhv) = pmnegwrtvh smgmdqmyim (qboudxylpp, 6.2)
-
04 Mar 2014
(Group 4)
nadfbtodlc(owcbonkyhv) = zmmhxqwplg smgmdqmyim (qboudxylpp, 6.2)
Not Applicable
83
qiegyoqxfk(osrtecuzeq) = utcywbpsqy zzcbbfbwsf (uojrahnpnn )
-
01 Apr 2012
qiegyoqxfk(osrtecuzeq) = rveosezatp zzcbbfbwsf (uojrahnpnn )
Phase 3
25
(Alfuzosin Solution - 2-7 Years)
zsmukrxbub = hcadoojwga mmumldvonr (oueklkhfal, aeaamgwqlw - nbrprojtpi)
-
08 Feb 2011
(Alfuzosin Solution - 8-16 Years)
zsmukrxbub = zhppkiivdi mmumldvonr (oueklkhfal, hbhdpjgqcd - otssthekrc)
Phase 3
172
Placebo
(Placebo)
nadmmgadlb = gyecoexsgd xycsxbbwbf (sejmttgvki, alsojmjnum - ztmckzbjkm)
-
08 Feb 2011
(Alfuzosin 0.1 mg/kg/Day)
nadmmgadlb = ihjerpwwoy xycsxbbwbf (sejmttgvki, bzftgyqqqu - tzrlyyduin)
Phase 3
1,522
Alfuzosin 10 mg once daily
kpyyyjjqmj(yrqqglixfp) = nyetbzrbyf zqtuspygjw (gdpelgoeph )
-
01 Apr 2006
Placebo
kpyyyjjqmj(yrqqglixfp) = qjrysqjpgt zqtuspygjw (gdpelgoeph )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free